Interview with Amit Mehta, Managing Director, S. Amit & Co
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Address: 101-A Neelam Centre, 249-B Hind Cycle Road, Worli, Mumbai 400 030, India
Tel: +91 22 4001 3000
S. Amit Speciality Chemicals Pvt. Ltd. is a leading full-service Chemistry Solutions provider in India delivering products and services in the areas of speciality chemicals, intermediates and performance chemicals for diverse applications including pharmaceuticals, agrochemicals, polymers & plastics, and paints and coating.
Over the last six decades, the Company has transitioned from representing international laboratory chemical suppliers to marketing 1 or 2 steps of chemistries to supplying advanced intermediates and performance chemicals such as reducing agents, resolving agents, encapsulated catalysts, etc. Focussed on its broad-based relationships with both customers and suppliers, the objective has always been to add value to the chemical supply chain for both parties.
Today, as an integrated solutions provider, the S. Amit Group of Companies focuses on offering a full range of supply chain services including – representation of manufacturers, global and local sourcing, distribution, virtual manufacturing, and identifying problems and recommending innovative chemical solutions. This allows our customers and suppliers to effectively extract value from the supply chain based on their needs and the market situation.
In January 2011, S. Amit acquired Reaxa U.K., a company actively involved in developing and supplying encapsulated metal catalysts for synthetic organic chemistry.
Through its various group companies, the S. Amit Group provides
Indenting
Local Sales and Distribution
Exports
Virtual Manufacturing Services
Products and services are branded through the following group companies – S. Amit, Finorga,
Chem Amit, Perfo Chem and Brom Chem
The S. Amit Group also has a joint venture company, Diamines & Chemicals Ltd. that manufactures piperazine at its plant in Baroda, Gujarat.
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
Satish Kumar Singh (managing director) & Shashi Shekhar Kumar (vice president International Business) from M/s Cachet Pharmaceuticals Pvt. Ltd., discuss their success with special reference to marketing, distribution and operating…
A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar…
A nationwide renowned neonatologist and member of the High Level Expert Group on Universal Health Coverage, NITI Aayog’s medical expert, Dr. Vinod K. Paul introduces the work that the government…
Newly appointed commissioner of the Food & Drugs Administration (FDA) of the Indian state of Maharashtra, Dr. Pallavi Darade, shares her objectives to further consolidate the FDA’s positioning as a…
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen –…
Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how…
Janmejay Vyas, chairman of the Dishman Group, shares the story of his success in establishing a trustworthy relationship with the strictest drug regulator in the world, the US FDA. Mr…
See our Cookie Privacy Policy Here
